J Nucl Med. 2008; 49 (Supplement 1):177P
Educational Exhibits (Poster Only)Oncology Posters |
FDG-PET/CT for the staging and the early prediction of chemotherapeutic response in testicular germ cell tumors
Ryogo Minamimoto1,
Hirofumi Shibata1,
Akiko Suzuki1,
Kazuya Shizukuishi1,
Jin Lee1,
Yoshinobu Kubota2 and
Tomio Inoue1
1 Department of Radiology;
2 Department of Urology, Yokohama City University, Yokohama, Japan
776
Learning Objectives: 1. Review the utility of FDG-PET/CT in testicular germ cell tumors. 2. Review the early prediction of chemotherapeutic response in testicular germ cell tumors by FDG-PET/CT. 3. Review the limitation in evaluating chemotherapeutic response with FDG-PET/CT.
Abstract Body: Testicular cancer is the most common solid malignancy in young males. Germ cell tumors account for over 90% of testicular cancers. The radiographic evaluation is used to assign a clinical stage, which is an essential guide of initial therapy for testicular germ cell tumors. FDG-PET is one of the non invasive diagnostic tool for imaging glucose metabolic process in germ cell tumors. Although FDG-PET is estimated to have a limited utility in the evaluation of initial staging, FDG-PET/CT has more advanced utility. Patients with germ cell tumor in stage II, which is the state of existing distant metastasis, are usually treated with chemotherapy or radiation therapy following orchiectomy. FDG-PET has a better result than CT in predicting chemotherapeutic response (after adequate therapy) and presence of advance in residual tumor. To examine further predictable possibility of chemotherapeutic response, we performed FDG-PET/CT to germ cell tumor patients in two periods, one for early stages (just before the 2nd cycle of chemotherapy), and the other for after adequate therapy (after 6th cycles of chemotherapy). In addition, we suggest the unexpected case with FDG-PET/CT in evaluating a presence of advance in residual tumor.
